Read by QxMD icon Read

Cytometry. Part B, Clinical Cytometry

Benjamin E J Spurgeon, Khalid M Naseem
Platelet flow cytometry is widely used in cardiovascular medicine as the platelet surface is rich in clinical biomarkers. Surface profiling is critical in disease management, but current assays can abet clinical errors as they are suboptimal and prone to bias. Accordingly, the technical and analytical advances that can be used to create high quality assays with minimal error and maximal sensitivity were reviewed. Specifically, the best practices for instrument setup, quality control, panel design, titration, gating, and compensation were described...
February 19, 2019: Cytometry. Part B, Clinical Cytometry
Marie Loosveld, Vanessa Nivaggioni, Isabelle Arnoux, Denis Bernot, Gérard Michel, Marie C Béné, Marion Eveillard
BACKGROUND: In children with acute lymphoblastic leukemia (ALL) low levels of minimal residual disease (MRD) after induction, essentially assessed in the bone marrow, have been shown to be of good prognosis. However, only few studies have tested the peripheral blood for MRD. METHODS: Here, we report the impact on survival of peripheral blood (PB) MRD assessment by multiparameter flow cytometry (MFC) at early time points of treatment in 125 B-ALL children, compared to Day 35 molecular bone marrow (BM) MRD...
February 7, 2019: Cytometry. Part B, Clinical Cytometry
Abdullah Alsuwaidan, Elaina Pirruccello, Jesse Jaso, Prasad Koduru, Rolando Garcia, JoEllen Krueger, Meggie Doucet, Rahman Chaudhry, Franklin Fuda, Weina Chen
BACKGROUND: High-grade B-cell lymphomas (HGBCL) with MYC and BCL2 or/and BCL6 rearrangements (R), so-called double/triple-hit lymphomas (DH/THL), are uncommon, clinically aggressive lymphomas that require a prompt diagnosis. We aim to identify flow cytometric immunophenotypic (IP) features of DH/THL that may aid in triaging these cases followed by a timely confirmatory cytogenetic study. METHODS: We compared the IP features of 43 cases of DH/THL to those of 55 cases of single-hit lymphoma (SHL) and 59 cases of diffuse large B-cell lymphoma (DLBCL) without MYC-R (MYCneg DLBCL)...
February 7, 2019: Cytometry. Part B, Clinical Cytometry
Alex Quach, Shannon Glowik, Trishni Putty, Antonio Ferrante
BACKGROUND: Neutrophils ex vivo in whole blood specimens are widely understood to decay rapidly when compared to other leukocytes, requiring assessment of neutrophil activity to be performed shortly after blood collection. There is a disparity in evidence for decay rates in measurements and recommended time-frames for assaying neutrophil parameters in particular assays following blood collection. We, therefore, evaluated the decline in the neutrophil respiratory burst, typically screened for assessing congenital NADPH oxidase defects, over a shorter time-course than previously published experiments...
February 7, 2019: Cytometry. Part B, Clinical Cytometry
Ildikó Beke Debreceni, Róbert Szász, Zoltán Kónya, Ferenc Erdődi, Flóra Kiss, János Kappelmayer
BACKGROUND: Adhesion receptors have important role in cellular invasiveness and L-selectin is a primary determinant in the binding of chronic lymphocytic leukemia (CLL) cells to several glycated proteins on endothelial cells. We investigated L-selectin expression on CLL cells and explored the mechanisms that lead to their shedding. METHODS: Surface and soluble L-selectin expression levels were studied by flow cytometry and immunoassay, respectively. Magnetically isolated B-cells from patients and controls were investigated for total and protein phosphatase-2A activities...
February 6, 2019: Cytometry. Part B, Clinical Cytometry
Dragan Jevremovic, Horatiu Olteanu
This article provides an overview of the role of flow cytometry in the diagnosis, prognosis, and follow-up of T and NK-cell lymphoproliferative disorders. For each category, we will briefly discuss the immunophenotypic features of normal T and NK cells, and address technical issues in flow cytometry, the approach to diagnosis in various contexts, pitfalls in interpretation, and its use in follow-up and post-therapy management. In addition to reviewing the diagnostic, prognostic, and therapeutic utility of flow cytometric immunophenotyping in several of specific T and NK cell entities, we will also cover some of the new immunophenotypic markers...
February 6, 2019: Cytometry. Part B, Clinical Cytometry
Nishit Gupta, Mayur Parihar, Sambhunath Banerjee, Subhajit Brahma, Ravikiran Pawar, Asish Rath, Sundar Shewale, Manish Singh, Arun Sasikumaran Nair Remani, Shekhar Krishnan, Arpita Bhatacharyya, Anirban Das, Jeevan Kumar, Saurabh Bhave, Vivek Radhakrishnan, Reena Nair, Mammen Chandy, Deepak Mishra, Neeraj Arora
BACKGROUND: Flow cytometry (FCM) is a simple, sensitive, and specific technique that can potentially determine DNA ploidy in B-cell precursor ALL (BCP-ALL) and is complementary to cytogenetics. METHODS: A prospective FCM DNA ploidy analysis using FxCycle™ Violet (assay sensitivity 0.01%) was done in 125 consecutive new cases of BCP-ALL (90 cases <15 years of age) and compared with corresponding cytogenetic ploidy (karyotyping and/or FISH) data wherever available...
February 4, 2019: Cytometry. Part B, Clinical Cytometry
Donatella Raspadori, Paola Pacelli, Anna Sicuranza, Elisabetta Abruzzese, Alessandra Iurlo, Daniele Cattaneo, Antonella Gozzini, Sara Galimberti, Claudia Baratè, Patrizia Pregno, Maura Nicolosi, Federica Sorà, Mario Annunziata, Luigiana Luciano, Giovanni Caocci, Sabrina Moretti, Nicola Sgherza, Claudio Fozza, Sabina Russo, Emilio Usala, Marina A Liberati, Sara Ciofini, Monika M Trawinska, Alessandro Gozzetti, Monica Bocchia
BACKGROUND: Recent investigations in chronic myeloid leukemia (CML) have focused on the identification and characterization of leukemic stem cells (LSCs). These cells reside within the CD34+ /CD38─ /Lin─ fraction and score positive for CD26 (dipeptidylpeptidase IV) a marker, expressed in both bone marrow (BM) and peripheral blood (PB) samples, that discriminates CML cells from normal hematopoietic stem cells (HSCs) or from LSCs of other myeloid neoplasms. CD26 evaluation could be a useful tool to improve the identification of CML LCSs by using flow-cytometry assay...
February 3, 2019: Cytometry. Part B, Clinical Cytometry
Lakhdar Bouriche, Denis Bernot, Vanessa Nivaggioni, Isabelle Arnoux, Marie Loosveld
BACKGROUND: Flow cytometry is a powerful tool for the detection of minimal residual disease (MRD) of B cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. However, the staining process and the choice of antibodies rely on laboratory expertise and may be source of variability or technical errors. Recently, Beckman Coulter commercialized a ready to use tube with dried format reagents for BCP-ALL MRD detection. The aim of this study is to evaluate the applicability of this tube and to compare it to a conventional (liquid format reagents) method...
January 30, 2019: Cytometry. Part B, Clinical Cytometry
Fatima Hamadeh, Amad Awadallah, Howard J Meyerson, Rose C Beck
BACKGROUND: Neoplasms derived from plasmacytoid dendritic cells (PDCs) are currently divided into two broad categories: mature PDC proliferations associated with myeloid neoplasms (MPDMN) and blastic plasmacytoid dendritic cell neoplasm (BPDCN); only BPDCN is recognized in the WHO 2016 classification of hematopoietic neoplasms. We present seven patients with high grade myeloid neoplasms (MNs), mostly acute leukemias, having a spectrum of PDC differentiation and not fitting with MPDMN or BPDCN...
January 5, 2019: Cytometry. Part B, Clinical Cytometry
Marc Sorigue, Minerva Raya, Sara Vergara, Edurne Sarrate, Elisa Orna, Jordi Juncà
BACKGROUND: The concept of borderline lymphoproliferative disorder (LPD) has not been clearly defined. METHODS: This study aimed to classify patients with leukemic LPD (n = 597, excluding hairy cell leukemia, mantle cell lymphomas, and CD10-positive LPDs) into CLL or non-CLL applying three diagnostic strategies (the D'Arena and CLLflow scores and CD43 expression) and to better characterize unclassified patients. RESULTS: Patients with concurring CLL-like (n = 441) or non-CLL like (n = 99) results with the three diagnostic strategies were determined to have CLL and non-CLL, respectively...
December 28, 2018: Cytometry. Part B, Clinical Cytometry
Daniel Mazza Matos
No abstract text is available yet for this article.
December 26, 2018: Cytometry. Part B, Clinical Cytometry
Stuart D Scott, Matthew Fletcher, Helen Whitehouse, Liam Whitby, Constance Yuan, Silvia Mazzucchelli, Pei Lin, Ruth de Tute, Pranav Dorwal, Paul K Wallace, Prashant Tembhare, Maria Arroz, John A Snowden, Andrew D Chantry, David Barnett
BACKGROUND: Minimal/measurable residual disease (MRD) testing by flow cytometry (FC) has been proposed as a potential surrogate clinical endpoint in plasma cell myeloma (PCM) clinical trials. As a result, effort has gone into standardizing this approach on PCM patients. AIMS: To assess inter-laboratory variation in FC MRD testing of PCM patients in an independent inter-laboratory study. METHODS: A dilution series of five stabilized bone marrow samples manufactured to contain 0%, 0...
December 19, 2018: Cytometry. Part B, Clinical Cytometry
Giovanni Rossi, Antonietta Pia Falcone, Maria Marta Minervini, Giovanni Pio De Cillis, Chiara De Waure, Leuconoe Grazia Sisti, Vincenzo Giambra, Daniela Valente, Vincenzo Chiello, Potito Rosario Scalzulli, Angelo Michele Carella, Nicola Cascavilla
BACKGROUND: Optimization of chemotherapy regimens in the treatment of multiple myeloma (MM) has led to increase the frequency of cases with complete response (CR). Nonetheless, many MM patients still experience relapse, suggesting that CR represents a suboptimal response criteria, and that new therapeutic strategies are needed after single transplant. However, the role of double autologous stem cell transplant (ASCT) as new adjunctive strategy remains to be elucidated. Indeed, we investigated the role of minimal residual disease (MRD) and log-reduction of plasma cells (PCs) as predictors of outcome and in quantifying the degree of tumor reduction after any ASCT...
December 13, 2018: Cytometry. Part B, Clinical Cytometry
Sa A Wang, Magdalena B Czader
No abstract text is available yet for this article.
December 13, 2018: Cytometry. Part B, Clinical Cytometry
Michel Ticchioni, Chantal Brouzes, Françoise Durrieu, Claude Lambert
BACKGROUND: As part of quality assurance in laboratories (labs) offering clinical cell analysis by flow cytometry (FCM), cell counting precision and robustness are evaluated but international desirable ranges are still missing. The aim of this study was to provide desirable interlaboratory variability reference values. METHODS: A prospective survey on monthly quality assessment was proposed to all French laboratories routinely performing lymphocyte subpopulation quantification, over one arbitrarily selected month (June 2017), regardless of instrument, counting system and quality controls used...
December 7, 2018: Cytometry. Part B, Clinical Cytometry
(no author information available yet)
We are pleased to present abstracts from ESCCA 2018: At the Shore of Future Cytometry. This year, the European Society for Clinical Cell Analysis (ESCCA) organised its annual Conference over 3 days in Valencia, Spain. Four workshops for a limited number of participants - dedicated to Cytometry Analysis Tools, Cytometry of Microparticles, Cytometry in Veterinary and Animal Sciences and CLL MRD - as well as ESCCA certification exams took place before the Conference. The Conference itself included four Education Programmes from which the participants had to choose in advance: (i) Good Cytometry Practices; (ii) Advanced Hemato-Oncology; (iii) Clinical Diagnostic Cytometry and (v) Advanced Immunology...
December 5, 2018: Cytometry. Part B, Clinical Cytometry
Fan Wu, Ying Pan, Huiping Wang, Qianshan Tao, Furun An, Jiakui Zhang, Zhimin Zhai
Hepatosplenic T-cell lymphoma (HSTCL) is a very rare non-Hodgkin lymphoma with an aggressive clinical course and poor prognosis. Patients of this disease usually presented with hepatosplenomegaly, which can be misdiagnosed or delayed. Bone marrow (BM) and peripheral blood (PB) are frequently involved, however, central nervous system (CNS) involvement is less common. Here, we are reporting an unusual case of hepatosplenic γδ T-cell lymphoma in a 64-year-old man with CNS involvement. Flow cytometry immunophenotyping was proved of great diagnostic contribution...
November 30, 2018: Cytometry. Part B, Clinical Cytometry
Titus Keller, Leonie Wengenroth, Denise Smorra, Kristina Probst, Leo Kurian, Angela Kribs, Bent Brachvogel
BACKGROUND: Human breast milk could be an important stem cell source for the development of newborn and preterm infants, but quantitative data on the stem cell content in breast milk at various gestational stages are needed to determine the clinical value of breast milk as a source of stem cells. Breast milk also contains milk fat globules, lipid droplets of different sizes, debris and dead cells and these components hamper flow cytometry analysis of human breast milk samples. METHODS: Here, we originally used standard protocols for flow cytometry to characterize cell populations in human breast milk but failed to discriminate between cells and noncellular components...
November 26, 2018: Cytometry. Part B, Clinical Cytometry
Frederic Preffer
No abstract text is available yet for this article.
January 2019: Cytometry. Part B, Clinical Cytometry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"